UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported) February 19,
2009
ORAMED PHARMACEUTICALS
INC.
(Exact
Name of Registrant as Specified in Its Charter)
Nevada
(State or
Other Jurisdiction of Incorporation)
|
000-50298
|
98-0376008
|
|
(Commission
File Number)
|
(IRS
Employer Identification
No.)
|
|
2
Elza Street, Jerusalem Israel
|
93706
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
972-54-7909058
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2.
below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On February 19, 2009, Chaime Orlev, the
Chief Financial Officer, Treasurer and Secretary of Oramed Pharmaceuticals, Inc.
(the “Company”) delivered to the Company a notice of resignation. Mr.
Orlev agreed to continue in the aforementioned positions at the request of the
Company until no later than March 31, 2009 in order to assist the Company with
the orderly transition of his duties to a successor. Mr. Orlev has
cited personal reasons for his departure and his
resignation did not arise from any disagreement with the Company on any
matter relating to the Company’s operations, policies or practices.
The Company has commenced the process
of identifying qualified candidates to serve as Chief Financial Officer and
Treasurer.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly
authorized.
|
ORAMED
PHARMACEUTICALS INC.
|
|
|
(Registrant)
|
|
|
By:
|
/s/ Nadav Kidron |
|
Nadav
Kidron
|
|
|
President,
CEO and
Director
|
|
Date: February
23, 2009